IgAÉö²¡ÊÇÈ«Çò¹æÄ£ÄÚ×î³£¼ûµÄÔ·¢ÐÔÉöСÇò¼²²¡Ö®Ò»£¬£¬£¬£¬£¬£¬£¬ÔÚÎÒ¹ú¼°¶«Ñǹú¼ÒÓÈΪ³£¼û¡£¡£¡£¡£¡£´ó´ó¶¼»¼ÕßÌåÏÖΪÉöÔಡ»ºÂýÏ£Íû£¬£¬£¬£¬£¬£¬£¬Êǵ¼ÖÂÇàÄêÈËÖÕδÆÚÉö²¡µÄ×î³£¼û²¡Òò£¬£¬£¬£¬£¬£¬£¬¸ø¼ÒÍ¥ºÍÉç»á´øÀ´Á˼«Öصļ²²¡¼ç¸º¡¾1¡¿¡£¡£¡£¡£¡£ÔÚIgAÉö²¡µÄÖÎÁÆÀú³ÌÖУ¬£¬£¬£¬£¬£¬£¬»¼Õß½ÌÓýÊÇÖ÷Òª»·½Ú£¬£¬£¬£¬£¬£¬£¬¶øÏÖÔÚIgAÉö²¡»¼Õߵļ²²¡ÈÏÖª¡¢×ÔÎÒ¹ÜÀíÄÜÁ¦ÈÔÓнϴóÌáÉý¿Õ¼äºÍδ֪×ãÐèÇ󡣡£¡£¡£¡£
ΪÁË×ÊÖú¸ü¶àIgAÉö²¡»¼Õß»ñÈ¡ÕïÁÆÖªÊ¶¡¢Ìá¸ß¼²²¡¹ÜÀíÄÜÁ¦£¬£¬£¬£¬£¬£¬£¬¡°ÊØÎÀÉö¹¦Ð§¡ªIgAÉöÓѰٳǹ«ÒæÐС±ÏîÄ¿³¤É³Õ¾Ô˶¯ÔÚZ6×ðÁú´óÒ©·¿ÎåÒ»Æðµê¾ÙÐУ¬£¬£¬£¬£¬£¬£¬Í¨¹ýÏßÉÏÏßÏÂÏàÍŽáµÄÉöÓѽÌÓýÔ˶¯¡¢Ò½»¼»¥¶¯¼°¿ÆÆÕÈö²¥£¬£¬£¬£¬£¬£¬£¬Íƶ¯»¼ÕßÔçÕïÔçÖΣ¬£¬£¬£¬£¬£¬£¬´Ó¶øÑÓ»º¼²²¡Ï£Íû£¬£¬£¬£¬£¬£¬£¬Ìá¸ßÉúÑÄÖÊÁ¿¡£¡£¡£¡£¡£
³¤É³ÊÐÉö´È¹«Òæ·þÎñÖÐÐÄÀíʳ¤ºî¼ÑÏÖ³¡Ö´ǣ¬£¬£¬£¬£¬£¬£¬·ÖÏí¹«ÒæÁ¦Á¿ÔÚÉö²¡Ôçɸ¡¢»¼Õß½ÌÓý¼°ÐÄÀíÖ§³ÖµÈ·½ÃæµÄʵ¼ùÂÄÀú¡£¡£¡£¡£¡£
±¾´ÎÔ˶¯Ô¼ÇëÁËÖÐÄÏ´óÑ§ÏæÑÅÈýÒ½ÔºÉöÄÚ¿ÆÁõ¼Íʵ½ÌÊÚ´øÀ´Ö÷Ìâ½²×ù£¬£¬£¬£¬£¬£¬£¬ÒÔÕæÊµ°¸Àý½â˵IgAÉö²¡µÄ·¢²¡ÌåÏÖ¡¢ÉúÑÄÒûʳÔÔò¡¢IgAÉö²¡Ò©ÎïÕïÁƼƻ®µÈ֪ʶ£¬£¬£¬£¬£¬£¬£¬ÃãÀø¸÷ÈË׼ȷÊìϤ¼²²¡£¡£¡£¡£¡£¬£¬£¬£¬£¬£¬£¬×öµ½ÔçÕï¡¢ÔçÖΡ¢Ô綨ÐÄ¡£¡£¡£¡£¡£
ÔÚÏÖ³¡´ðÒÉ»·½Ú£¬£¬£¬£¬£¬£¬£¬Áõ¼Íʵ½ÌÊÚÕë¶Ô»¼ÕßÌåÌùµÄÎÊÌâÖðÒ»½â´ð¡£¡£¡£¡£¡£¹ØÓÚÐí¶àÉöÓÑÌåÌùµÄ²¼µØÄ峦ÈܽºÄÒµÄÎÊÌ⣬£¬£¬£¬£¬£¬£¬Áõ½ÌÊÚ½â´ð£º²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÊÇÈ«ÇòÊ׸ö°ÐÏòIgAÉö²¡Ô´Í·–³¦µÀð¤Ä¤ÃâÒߵĶÔÒòÖÎÁÆÐÂÒ©£¬£¬£¬£¬£¬£¬£¬ÊÇÊ׸öͬʱ±»ÃÀ¹úFDA¡¢Å·ÖÞEMA¡¢ÖйúNMPAÈý´óȨÍþÒ©¼à»ú¹¹Åú×¼ÓÃÓÚÖÎÁÆIgAÉö²¡µÄÁ¢ÒìÒ©Î2-7¡¿£¬£¬£¬£¬£¬£¬£¬¾ßÓÐÖØ´óÁÙ´²ÒâÒå¡£¡£¡£¡£¡£ËüÊÊÓÃÓÚ¾ßÓÐÏ£ÍûΣº¦µÄÔ·¢ÐÔIgAÉö²¡³ÉÄ껼Õߣ¬£¬£¬£¬£¬£¬£¬¿ÉÒÔïÔÌÉö¹¦Ð§Ëðʧ£¬£¬£¬£¬£¬£¬£¬Í¬Ê±½µµÍÂѰ×Äò¡¢¸ÄÉÆÑªÄò¡£¡£¡£¡£¡£
²¼µØÄ峦ÈܽºÄÒ£¨Ä͸³¿µ?NEFECON?£©ÔÚZ6×ðÁú´óÒ©·¿ÓÐÊÛ£¬£¬£¬£¬£¬£¬£¬ÎÒÃÇÆð¾¢ÅäºÏÁÙ´²ÐèÇ󣬣¬£¬£¬£¬£¬£¬ÊµÊ±ÎÈÍ׵ؽ«Ò©Æ·ÅäË͵½»¼ÕßÐèÒªµÄµØ·½¡£¡£¡£¡£¡£
Z6×ðÁú²¿·ÖDTPÒ©·¿ÐÅÏ¢Ò»ÀÀ£º
²Î¿¼ÎÄÏ×£º
1.ÐÂÒ©Ó¦ÓúÍÖÎÁÆÕ½ÂÔת±äÓÐÍû¸ÄÉÆIgAÉö²¡»¼ÕßµÄÔ¤ºó[J]. ÖлªÒ½Ñ§ÐÅÏ¢µ¼±¨,2024,39(16):11. DOI:10.3760/cma.j.issn.1000-8039.2024.16.118.
2.https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20231124144653113.html.
3.FDA approves first drug to decrease urine protein in IgA nephropathy, a rare kidney disease
4.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.
5.https://www.calliditas.se/en/calliditas-therapeutics-announces-full-fda-approval-of-tarpeyo-the-only-fda-approved-treatment-for-iga-nephropathy-to-significantly-reduce-the-loss-of-kidney-function/
6.https://www.everestmedicines.com/zhhans/news/yundingxinyaohezuohuobancalliditasxuanbunaifukanghuodemeiguofdawanquanpizhunyongyuzhiliaoyoujinzhanfengxiandeigashenbinghuanzhe-wulunqijixiandanbainiaoshuiping/936f18ac-566a-4b3d-8cd0-036f720b62e6/
7.https://news.cision.com/calliditas-therapeutics/r/european-commission-approves-kinpeygo--for-adults-with-primary-iga-nephropathy,c3600434.